Project Studie CDRB436F2302T - EADO ADAPT-BIO

Basic data

Title:
Studie CDRB436F2302T - EADO ADAPT-BIO
Duration:
18/12/2018 to 31/12/2026
Abstract / short description:
Clinical trial known as Adjuvant dabrafenib plus trametinib in high risk stage II BRAF mutated melanoma. A randomized double blind placebo controlled phase III trial with biomarker based patient selection
Keywords:
melanoma
Melanom
biomarker
Biomarker
BRAF

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Basel, Switzerland
Help

will be deleted permanently. This cannot be undone.